Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lonza Group | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 39.83B | 58x | CHF 548.40 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.5% Upside | Upgrade to Pro+ | ||
Lonza Group | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 39.83B | 58x | CHF 548.40 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.5% Upside | Upgrade to Pro+ | ||
BACHEM HOLDING AG | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 4.04B | 33.8x | 4.94 | CHF 53.60 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 38.2% Upside | Upgrade to Pro+ | |
BB Biotech | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 1.93B | 25.6x | 0.19 | CHF 35.20 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 1.91B | 26.7x | 0.19 | CHF 34.85 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Kuros Biosciences | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 744.44M | -140.3x | -2.68 | CHF 19.58 | 3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Basilea Pharmaceutica AG | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 573.74M | 7.4x | 0.01 | CHF 47.35 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.7% Upside | Upgrade to Pro+ | |
Idorsia | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 250.62M | -0.8x | -0.07 | CHF 1.13 | 2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -15.3% Downside | Upgrade to Pro+ | |
Bioversys Ag | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 202.03M | CHF 35.70 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
Newron Pharmaceuticals | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 167.85M | -8.5x | 0.59 | CHF 8.42 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Molecular Partners AG | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 134.59M | -2.3x | -0.17 | CHF 3.69 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Xlife Sciences | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 111.68M | 11.8x | 0.32 | CHF 19.50 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Relief Therapeutics | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 32.86M | -0.4x | CHF 2.61 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Addex Therapeutics Ltd | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 5.51M | 1x | -0 | CHF 0.06 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |